7.00
0.24 (3.55%)
| Previous Close | 6.76 |
| Open | 6.90 |
| Volume | 796,431 |
| Avg. Volume (3M) | 1,093,883 |
| Market Cap | 5,632,318,976 |
| Price / Earnings (TTM) | 28.00 |
| Price / Earnings (Forward) | 10.99 |
| Price / Sales | 0.730 |
| Price / Book | 0.890 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Profit Margin | 2.65% |
| Operating Margin (TTM) | 16.42% |
| Diluted EPS (TTM) | 0.270 |
| Quarterly Revenue Growth (YOY) | 9.80% |
| Quarterly Earnings Growth (YOY) | 178.80% |
| Total Debt/Equity (MRQ) | 121.14% |
| Current Ratio (MRQ) | 2.60 |
| Operating Cash Flow (TTM) | 1.20 B |
| Levered Free Cash Flow (TTM) | 2.26 B |
| Return on Assets (TTM) | 3.99% |
| Return on Equity (TTM) | 3.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Bearish | Mixed |
| Drug Manufacturers - General (Global) | Bearish | Mixed | |
| Stock | Grifols, S.A. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.50 |
|
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Mid Growth |
| % Held by Institutions | 58.60% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Permian Investment Partners, Lp | 31 Dec 2024 | 16,187,321 |
| 52 Weeks Range | ||
| Median | 10.30 (47.14%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 17 Jun 2025 | 10.30 (47.14%) | Hold | 8.87 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 May 2025 | Announcement | Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting |
| 5Y Average Dividend Yield | 1.03% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 03 Jun 2021 | 21 May 2021 | 14 Jun 2021 | 0.456586 Cash |
| 30 Oct 2020 | 16 Oct 2020 | 09 Nov 2020 | 0.201439 Cash |
| 02 Dec 2019 | 31 Oct 2019 | 11 Dec 2019 | 0.221872 Cash |
| 07 Jun 2019 | 29 May 2019 | 18 Jun 2019 | 0.175638 Cash |
| 30 Nov 2018 | 07 Nov 2018 | 11 Dec 2018 | 0.22789 Cash |
| 01 Jun 2018 | 25 May 2018 | 12 Jun 2018 | 0.250975 Cash |
| 01 Dec 2017 | - | 12 Dec 2017 | 0.212979 Cash |
| 30 May 2017 | - | 08 Jun 2017 | 0.163528 Cash |
| 05 Dec 2016 | - | 14 Dec 2016 | 0.193644 Cash |
| 02 Jun 2016 | - | 15 Jun 2016 | 0.162059 Cash |
| 10 Dec 2015 | - | 17 Dec 2015 | 0.384765 Cash |
| 08 Jun 2015 | - | 15 Jun 2015 | 0.341846 Cash |
| 04 Dec 2014 | - | 12 Dec 2014 | 0.312792 Cash |
| 05 Jun 2013 | 24 May 2013 | 13 Jun 2013 | 0.258668 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2021 | 0.457 | 1 | 4.07 |
| 2020 | 0.201 | 1 | 1.09 |
| 2019 | 0.398 | 2 | 1.71 |
| 2018 | 0.479 | 2 | 2.61 |
| 2017 | 0.377 | 2 | 1.64 |
| 2016 | 0.356 | 2 | 2.21 |
| 2015 | 0.727 | 2 | 4.49 |
| 2014 | 0.313 | 1 | 1.84 |
| 2013 | 0.259 | 1 | 1.43 |
| Show more | |||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |